PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND HMG COA REDUCTASE INHIBITORS.

摘要

A novel combination therapy is described for cardiovascular diseases or conditions, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor.